InvestSMART

ORDINARY FULLY PAID (ASX: OPT) - Announcements

DELISTED - Current share price for OPT : $0.013

ASX company news and announcements for ORDINARY FULLY PAID (OPT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All ORDINARY FULLY PAID (OPT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than ORDINARY FULLY PAID (OPT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for ORDINARY FULLY PAID (OPT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$18 Opthea Doses wAMD Patients in Europe and Israel 27 Mar 2018 8:59AM $0.580 $0.013 fallen by 97.76%
$18 Opthea Half Year Report and Accounts 19 Feb 2018 9:18AM $0.580 $0.013 fallen by 97.76%
$18 Appendix 3B 12 Jan 2018 9:11AM $0.670 $0.013 fallen by 98.06%
$18 Opthea Corporate Presentation - January 2018 8 Jan 2018 9:03AM $0.710 $0.013 fallen by 98.17%
$18 Opthea Receives A$2.7m R&D Tax Incentive 8 Jan 2018 9:00AM $0.710 $0.013 fallen by 98.17%
$18 Opthea Initiates OPT-302 Diabetic Macular Edema Trial 3 Jan 2018 8:28AM $0.700 $0.013 fallen by 98.14%
$18 Change in substantial holding 22 Dec 2017 11:58AM $0.665 $0.013 fallen by 98.05%
$18 Change in substantial holding (Full copy) 19 Dec 2017 10:19AM $0.720 $0.013 fallen by 98.19%
$18 Opthea Doses First Patient in OPT-302 wAMD Ph2b trial 19 Dec 2017 9:31AM $0.720 $0.013 fallen by 98.19%
$18 Change in substantial holding 19 Dec 2017 9:30AM $0.720 $0.013 fallen by 98.19%
$18 Appendix 3B 15 Dec 2017 9:15AM $0.720 $0.013 fallen by 98.19%
$18 Results of Meeting 23 Nov 2017 3:00PM $0.690 $0.013 fallen by 98.12%
$18 Opthea CEO Presentation to the 2017 AGM 23 Nov 2017 9:37AM $0.690 $0.013 fallen by 98.12%
$18 Opthea Chairman's Address to the 2017 AGM 23 Nov 2017 9:35AM $0.690 $0.013 fallen by 98.12%
$18 Appendix 3B 21 Nov 2017 9:59AM $0.700 $0.013 fallen by 98.14%
$18 Notice of Annual General Meeting and Proxy Form 23 Oct 2017 8:22AM $0.720 $0.013 fallen by 98.19%
$18 Opthea Granted Key United States Patent Covering OPT-302 31 Aug 2017 9:24AM $0.690 $0.013 fallen by 98.12%
$18 Appendix 4G and Corporate Governance Statement 2017 30 Aug 2017 9:15AM $0.690 $0.013 fallen by 98.12%
$18 Opthea Appendix 4E and Annual Report 2017 30 Aug 2017 9:05AM $0.690 $0.013 fallen by 98.12%
$18 Opthea Presents Further Positive Data from OPT-302 Ph1/2A 15 Aug 2017 8:19AM $0.795 $0.013 fallen by 98.36%
$18 Opthea presentation for Ophthalmology Innovation Summit 11 Aug 2017 9:17AM $0.750 $0.013 fallen by 98.27%
$18 Opthea Presents at the Ophthalmology Innovation Summit 11 Aug 2017 9:09AM $0.750 $0.013 fallen by 98.27%
$18 Opthea to present at the ASRS Annual Meeting and the OIS 9 Aug 2017 8:23AM $0.735 $0.013 fallen by 98.23%
$18 Opthea to Present at Wedbush PacGrow Conference 1 Aug 2017 8:32AM $0.735 $0.013 fallen by 98.23%
$18 Opthea Allowed Key Patent for OPT-302 in United States 6 Jul 2017 8:53AM $0.780 $0.013 fallen by 98.33%

651 - 675 of 733 results

Page 27 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.